Shionogi & Co (4507) Q3 2026 earnings summary

Executive summary

• Achieved record highs in revenue, operating profit, and profit attributable to owners of the parent for the cumulative third quarter, driven by core business growth, domestic and overseas sales, and one-off gains from M&A activities.

• Strategic business investments included additional investment in ViiV Healthcare, acquisition of JT Group's pharmaceutical business, Torii Pharmaceutical, Akros Pharma Inc., and expansion into rare diseases via the edaravone business.

Financial highlights

• Revenue for the nine months ended December 31, 2025, was ¥360.7 billion, up 8.1% year-over-year, with quarterly revenue at ¥147.7 billion.

• Operating profit reached ¥148.7 billion (up 15.1%), and profit attributable to owners of parent was ¥158.2 billion (up 18.3%) for the nine-month period.

• EBITDA for the period was ¥147.8 billion, showing steady progress toward the full-year forecast.

• Comprehensive income rose 31.5% to ¥207.9 billion.

• Basic earnings per share increased to ¥185.95 from ¥157.30 year-over-year.

Outlook and guidance

• On track to achieve full-year forecasts, with FY2026 revenue projected at ¥500 billion (+14.1%), operating profit at ¥185 billion (+18.1%), and profit attributable to owners of parent at ¥188 billion (+10.3%).

• No revisions to the previously announced forecast.

• Business investments and R&D prioritization are expected to drive medium- to long-term growth.